Immunovant Inc (Immunovant), a subsidiary of Roivant Sciences Ltd, is a biopharmaceutical company that develops antibodies for the treatment of autoimmune diseases. The company’s pipeline products include batoclimab and MVT-1402. Its batoclimab treats myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and graves disease. It is also evaluating its IMVT-1402, for the treatment of autoimmune disease. The company seeks to collaborate with HanAll Biopharma Co Ltd for the research and development of next-generation FcRn inhibitors. The company operates in Switzerland, Bermuda and the US. Immunovant is headquartered in New York, the US.
Headquarters
United States of America
Address
320 West 37th Street, New York, 10018
Website
immunovant.com
Telephone
1 917 5803099
No of Employees
164
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
IMVT (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-34.6%
(2022 vs 2021)
Market Cap*
$4.0B
* As of and is in US$
Immunovant Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Batoclimab: Myasthenia Gravis, Thyroid Eye Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Graves Disease |
| IMVT-1402: Autoimmune Disease |
Competitor Comparison
| Key Parameters | Immunovant Inc | Alexion Pharmaceuticals Inc | Argenx SE | Hyliion Holdings Corp | Momenta Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Netherlands | United States of America | United States of America |
| City | New York | Boston | Amsterdam | Cedar Park | Cambridge |
| State/Province | New York | Massachusetts | Noord-Holland | Texas | Massachusetts |
| No. of Employees | 164 | 3,000 | 1,148 | 85 | - |
| Entity Type | Public | Private | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frank Torti, M.D. | Chairman | Executive Board | 2021 | 44 |
| Peter Salzmann, M.D. | Chief Executive Officer | Senior Management | 2019 | 55 |
| Renee Barnett | Chief Financial Officer | Senior Management | 2021 | 43 |
| Jay S. Stout | Chief Technology Officer | Senior Management | 2020 | - |
| Mark S. Levine | Chief Legal Officer; Secretary | Senior Management | 2022 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer